President & CEO Leen Kawas, PhD of M3 Biotechnology, Inc. to Be Interviewed Live on Clear Channel’s “The Trader’s Network Show”
Live Interview to Air March 14th, 2015 Hosted by Michael Yorba, 1:30PM ET / 10:30AM PT / 12:30PM CT
SEATTLE, WA–(Mar 13, 2015) – Leen Kawas, Ph.D, CEO of an innovative young therapeutics company named M3 Biotechnology, Inc., that has a novel platform of drugs which could reverse the course of neurodegenerative diseases like Parkinson’s Disease and Alzheimer’s by inducing brain cells to grow again, will be interviewed on a Clear Channel iHeart Business Radio’s live worldwide stream.
Kawas will be interviewed live on Saturday, March 14, 2015, at 1:30 p.m. ET by host Michael Yorba on “The Trader’s Network,” to discuss M3’s growth-factor-modifying pharmaceuticals platform that has begun to attract significant interest having completed animal trials and now moving toward human trials.
We encourage all shareholders, analysts, industry professionals and interested parties to tune in live. The details and link to iHeart Radio’s live worldwide steam are below.
Date: March 14, 2015
Start Time: 1:30pm ET | 10:30am PT | 12:30pm CT
Network: Clear Channel/ iHeart Radio
Station: DFW 1190AM KFXR
KFXR Show: The Traders Network Show
Host: Michael Yorba
Live iHeart Radio Stream: http://www.iheart.com/live/4276/?autoplay=true
About Clear Channel
Clear Channel’s Media and Entertainment division has the largest reach of any radio or television outlet in America with 243 million monthly listeners. It serves 150 cities through 850 owned radio stations in the U.S., as well as more than 140 stations in New Zealand and Australia. For more information visit its website at www.clearchannel.com.
About the Traders Network Show
For the past six years “The Traders Network Show” has been hosted and broadcasted live daily on Clear Channel DFW 1190AM KFXR from 7am – 8am, Monday-Friday and Saturdays from 1pm – 3pm ET. Host Michael Yorba interviews the front-page titans about the latest in capital markets, CEO milestones, trading tools, real estate acquisitions and market trends. Learn how the experts use risk management techniques to build fully diversified portfolios and what it takes to put up big board earnings. It’s a fast moving, high-energy show that presents stocks, commodities, bonds, forex, derivatives, real estate, political trends, technology trends, crowd funding and investment insights in a new light and keeps audiences asking for more… shift your thinking and join us as we deliver “tomorrow’s ideas today” on iHeart Radio and Clear Channel’s The Traders Network Show.
About President and CEO Leen Kawas, PhD.
The young firm where Kawas became CEO on late 2013 has developed a drug, now moving toward initial human trials, a drug that would not merely slow but actually reverse the course of neurodegenerative diseases like Parkinson’s Disease and Alzheimer’s. Dr. Kawas was co-inventor of the drug and co-founder of M3.
In addition to co-inventing the drug MM-201 and guiding the company toward its funding goals, M3’s scientist has successfully obtained grant-funding from noteworthy national organizations like the National Institutes of Health, the Alzheimer’s Drug Discovery Fund and the Michael J. Fox Foundation and impressive grant support from the Life Science Discovery Fund in Washington State.
M3’s drug is not merely a novel technology to addressing the neurodegenerative diseases but the approach for which she plans to seek FDA approval is also novel, taking advantage of a fast-track designation the FDA has approved to dramatically reduce the time and data required to enhance efficiency in getting drugs to market.
Kawas unique combination of scientific and medical knowledge, starting her career as a clinical pharmacist and then getting her PhD in molecular Pharmacology, give her the credibility to lead the company in its next research-intensive phase. While growing the company’s science and licensing the technology out of Washington State University, Kawas was also able to raise more than $2 million from both dilutive and non-dilutive sources, including grants from the National Institute of Health (NIH), Alzheimer’s Drug Discovery and Michael J Fox Foundations, to support development of the therapeutics being advanced in M3, especially MM-201. Dr. Kawas’ goal and passion is entrepreneurship that leads to disease modifying pharmaceuticals that address critical unmet medical needs. And as a female entrepreneur with a scientific background, Kawas is committed to mentoring women in science and business and has been selected for programs to inspire women to go into those fields, and was featured as a role model for women in a profile recently in a Spokane, WA business magazine. For Kawas, the challenge of raising investment capital for her start-up company while overcoming the array of obstacles facing a 29-year-old Middle Eastern female are more than offset by the successes she has been able to achieve.
About M3 Biotechnology, Inc.
M3 is preparing for a Phase I clinical trial of its patented small molecule therapy, MM-201. MM-201 is an orally delivered drug that causes stem cells to differentiate into neuron cells at a rate faster than degenerative brain diseases, such as Parkinson’s and Alzheimer’s, destroys them. During this trial, it is expected that M3 will enter into a license agreement with one of six large pharmaceutical companies to complete the FDA approval process and prepare for commercially manufacturing and marketing the drug. As a disease modifying and feasibly delivered drug, it is expected that MM201 will become the standard of care for patients afflicted with these diseases.
MM-201, with its first-in-class growth actor-activation process and unique small-molecule characteristic, which represents an important opportunity for potential investors as M3 raises the funds necessary to enable MM-201 to move through human trials and to market. The uniqueness of MM-201 is that it is orally available, able to permeate the protective blood brain barrier and thus modify the effects of Parkinson’s disease (PD) and Alzheimer’s disease (AD).
M3’s initial development work has been supported by grants from both the Michael J. Fox Foundation and the Alzheimer’s Drug Discovery Foundation, Life Science Discovery fund financial support stemming from the understanding of those foundations of the novel paradigm that M3’s technology represents. This support shows the understanding that M3’s technology could, for the first time in a non-invasive way as compared to Deep Brain Stimulation and other technologies in the pipeline, stop and possibly reverse the clinical course of these diseases. In addition to the life-altering potential of this drug, success would quickly lead to domination in a multi-billion-dollar market.
The drug has demonstrated efficacy in numerous animal models of neurodegenerative disease (NDD) including the rat scopolamine dementia model, the aged rat dementia model and the Rat 6-OHDA model of PD.
A CommPro Worldwide PR Event
PR & Media Contact:
Matt Bird, CEO
C: +1 (646) 401-4499